Clarification of Conflict of Interest Disclosures: In the Editorial entitled “Hospitalizations for Heart Failure in the United States—A Sign of Hope,” published in the October 19, 2011, issue of JAMA (2011;306:1705-1706), and in the Commentary entitled “A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes,” published in the April 27, 2011, issue of JAMA (2011;305:1702-1703), the conflict of interest disclosure information for Dr Braunwald should have read as follows: Dr Braunwald reported receiving research support from Merck, AstraZeneca, Johnson & Johnson, Beckman Coulter, Eli Lilly, Roche Diagnostics, sanofi-aventis, Daiichi Sankyo, GlaxoSmithKline, Bristol-Myers Squibb, and Pfizer as well as participating in symposia, advisory board meetings, and/or consultancies for the following companies: Eli Lilly, Merck, Genzyme, Amorcyte, CVRx (no compensation), The Medicines Company, CV Therapeutics, Daiichi Sankyo, MC Communications, Ortho McNeil, Ikaria, Menarini International, CardioRentis, and sanofi-aventis. Also in the Commentary, the conflict of interest disclosure for Dr Gheorghiade should have read as follows: Dr Gheorghiade reported that he received consulting fees from Bayer, Novartis, Sigma Tau, Johnson & Johnson, Takeda, Otsuka, and Medtronic. These 2 articles were corrected online. A letter regarding the differences in Dr Braunwald's conflict of interest disclosures appears in this issue.
Clarification of Conflict of Interest Disclosures in: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes. JAMA. 2012;307(6):563. doi:10.1001/jama.2012.113